camostat has been researched along with Colicky Pain in 4 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease." | 9.14 | Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. ( Inami, K; Kubokawa, Y; Matsumura, Y; Sai, JK; Suyama, M; Watanabe, S, 2010) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 7.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease." | 5.14 | Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. ( Inami, K; Kubokawa, Y; Matsumura, Y; Sai, JK; Suyama, M; Watanabe, S, 2010) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 3.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "Camostat mesilate, an orally available proteinase inhibitor, is clinically used for treatment of pancreatitis." | 3.74 | The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents. ( Ishiki, T; Ishikura, H; Kamanaka, Y; Kawabata, A; Matsunami, M; Nakatani, T; Naruse, M; Nishimura, S; Sekiguchi, F; Tsujiuchi, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamawaki, H | 1 |
| Futagami, S | 1 |
| Kaneko, K | 1 |
| Agawa, S | 1 |
| Higuchi, K | 1 |
| Murakami, M | 1 |
| Wakabayashi, M | 1 |
| Sakasegawa, N | 1 |
| Kodaka, Y | 1 |
| Ueki, N | 1 |
| Gudis, K | 1 |
| Kawamoto, C | 1 |
| Iwakiri, K | 1 |
| Sai, JK | 1 |
| Suyama, M | 1 |
| Kubokawa, Y | 1 |
| Matsumura, Y | 1 |
| Inami, K | 1 |
| Watanabe, S | 1 |
| Inoue, N | 1 |
| Ito, T | 1 |
| Akashi, T | 1 |
| Kawabe, K | 1 |
| Oono, T | 1 |
| Gibo, J | 1 |
| Arita, Y | 1 |
| Nawata, H | 1 |
| Funakoshi, A | 1 |
| Ishikura, H | 1 |
| Nishimura, S | 1 |
| Matsunami, M | 1 |
| Tsujiuchi, T | 1 |
| Ishiki, T | 1 |
| Sekiguchi, F | 1 |
| Naruse, M | 1 |
| Nakatani, T | 1 |
| Kamanaka, Y | 1 |
| Kawabata, A | 1 |
1 trial available for camostat and Colicky Pain
| Article | Year |
|---|---|
Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease.
Topics: Abdominal Pain; Adult; Aged; Dyspepsia; Endosonography; Esters; Female; Gabexate; Guanidines; Humans | 2010 |
3 other studies available for camostat and Colicky Pain
| Article | Year |
|---|---|
Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities.
Topics: Abdominal Pain; Aged; Benzamides; Drug Therapy, Combination; Dyspepsia; Esters; Female; Gabexate; Ga | 2019 |
Acute pancreatitis in the early stages of pregnancy associated with a PSTI gene mutation.
Topics: Abdominal Pain; Acute Disease; Adult; Amino Acid Substitution; Amylases; Carrier Proteins; Diet, Fat | 2004 |
The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents.
Topics: Abdominal Pain; Animals; Ceruletide; Dose-Response Relationship, Drug; Esters; Gabexate; Guanidines; | 2007 |